University of Kentucky

UKnowledge
Preventive Medicine and Environmental Health
Faculty Publications

Preventive Medicine and Environmental Health

3-6-2012

Fibrinogen, Chronic Obstructive Pulmonary Disease (COPD) and
Outcomes in Two United States Cohorts
Deepa Valvi
University of Kentucky, deepa.valvi@uky.edu

David M. Mannino
University of Kentucky, dmannino@uky.edu

Hana Müllerova
GlaxoSmithKline, United Kingdom

Ruth Tal-Singer
GlaxoSmithKline

Follow this and additional works at: https://uknowledge.uky.edu/pmeh_facpub
Part of the Environmental Public Health Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Repository Citation
Valvi, Deepa; Mannino, David M.; Müllerova, Hana; and Tal-Singer, Ruth, "Fibrinogen, Chronic Obstructive
Pulmonary Disease (COPD) and Outcomes in Two United States Cohorts" (2012). Preventive Medicine
and Environmental Health Faculty Publications. 27.
https://uknowledge.uky.edu/pmeh_facpub/27

This Article is brought to you for free and open access by the Preventive Medicine and Environmental Health at
UKnowledge. It has been accepted for inclusion in Preventive Medicine and Environmental Health Faculty
Publications by an authorized administrator of UKnowledge. For more information, please contact
UKnowledge@lsv.uky.edu.

Fibrinogen, Chronic Obstructive Pulmonary Disease (COPD) and Outcomes in
Two United States Cohorts
Digital Object Identifier (DOI)
http://dx.doi.org/10.2147/COPD.S29892

Notes/Citation Information
Published in International Journal of Chronic Obstructive Pulmonary Disease, v. 7, p. 173-182.
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution Non Commercial (unported, v3.0) License. The full terms of the License are available at
http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without
any further permission from Dove Medical Press Limited, provided the work is properly attributed.
Permissions beyond the scope of the License are administered by Dove Medical Press Limited.
Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

This article is available at UKnowledge: https://uknowledge.uky.edu/pmeh_facpub/27

International Journal of COPD

Dovepress
open access to scientific and medical research

O rigi n al R esearch

Open Access Full Text Article

Fibrinogen, chronic obstructive pulmonary
disease (COPD) and outcomes in two
United States cohorts
This article was published in the following Dove Press journal:
International Journal of COPD
6 March 2012
Number of times this article has been viewed

Deepa Valvi 1
David M Mannino 1,2
Hana Müllerova 3
Ruth Tal-Singer 4
1
Department of Preventive Medicine
and Environmental Health, University
of Kentucky College of Public Health,
Lexington, KY, USA; 2Department
of Pulmonary, Critical Care, and Sleep
Medicine, University of Kentucky
College of Medicine, Lexington, KY,
USA; 3GlaxoSmithKline Research
and Development, Worldwide
Epidemiology, Stockley Park,
Middlesex, UK; 4GlaxoSmithKline
Research and Development,
Respiratory Therapy Area Unit,
King of Prussia, PA, USA

Background: Fibrinogen is a marker of systemic inflammation and may be important in the
pathogenesis and progression of chronic obstructive pulmonary disease (COPD).
Methods: We used baseline data from Atherosclerosis Risk in Communities and Cardiovascular
Health Studies to determine the relation between fibrinogen levels and COPD and to examine
how fibrinogen levels at baseline affected outcomes of death, development of COPD, lung
function decline, and COPD-hospitalizations.
Results: Our study sample included 20,192 subjects, of whom 2995 died during the
follow-up period. The mean fibrinogen level was 307.6 mg/dL and 10% of the sample had
levels .393.0 mg/dL. Subjects with Stage 3 or 4 COPD were more likely to have a fibrinogen
level .393.0 mg/dL (odds ratio 2.28, 95% confidence interval [CI]: 1.79–2.95). In the longitudinal
adjusted models, fibrinogen levels .393 mg/dL predicted mortality (hazards ratio 1.54, 95%
CI: 1.39–1.70), COPD-related hospitalization (hazards ratio 1.45, 95% CI: 1.27–1.67), and
incident Stage 2 COPD (odds ratio 1.36, 95% CI: 1.07–1.74). Similar findings were seen with
continuous fibrinogen levels.
Conclusion: In the Atherosclerosis Risk in Communities/Cardiovascular Health Studies cohort
data, higher fibrinogen levels are predictors of mortality, COPD-related hospitalizations, and
incident Stage 2 COPD.
Keywords: COPD, fibrinogen, epidemiology, mortality, hospitalization
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Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease with varied
clinical presentations.1 COPD became the third leading cause of death in the United
States in 2008.2 Approximately one in 20 deaths in the United States had COPD as the
underlying cause.2 Understanding the natural history of COPD has been important in
the field of pulmonary medicine, dating back to the work of Burrows et al,3 and Fletcher
et al.4 Over subsequent years researchers have championed different hypotheses about
COPD development, including the British hypothesis stating that the presence of cough
and sputum was the key factor5 and the Dutch hypothesis stating that the presence of
increased airways responsiveness was the major factor.6
Fibrinogen is an inflammatory marker that is increased in COPD, as well as many
other inflammation-associated diseases.7 The Coronary Artery Risk Development
in Young Adults CARDIA study showed fibrinogen as a marker for chronic lowgrade inflammation and is associated with modest deterioration of lung function
in healthy young adults.8 According to Dahl and colleagues, increased levels of
fibrinogen were associated with reduced lung function and increased risk of COPD,
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and these associations were independent of smoking status.9
Groenewegen and colleagues demonstrated that besides lung
function impairment systemic inflammation manifested by
elevated fibrinogen levels was an independent risk factor for
exacerbations of COPD.10 Hyperfibrinogenemia is linked
with asthma11 and smoking.12 There is little information on
the relationship between plasma fibrinogen levels and lung
function decline;8 although recent work has suggested that
systemic processes may be important in these processes.
We hypothesized that fibrinogen can be used as a tool
for stratifying COPD patients in clinical trials by identifying
populations at higher risk for poor outcomes such as development of COPD, rapidly declining lung function, COPD
hospitalizations, and death. This paper examines the descriptors of normal and elevated fibrinogen levels at baseline in a
cohort of US adults and determines the relationship between
elevated fibrinogen levels and incident respiratory outcomes
including development of COPD, rapidly declining lung
function, COPD hospitalizations, and death controlling other
risk factors, including cardiovascular disease (CVD).

Methods
Study population
The study population originated from the combined cohorts
of the Atherosclerosis Risk in Communities (ARIC) and
Cardiovascular Health Study (CHS). Both the ARIC and CHS
were population-based National Institute of Health cohorts
initiated in the late 1980s.
The ARIC study was initiated in 1987 as a longitudinal,
population-based study of the etiology and clinical sequelae of
atherosclerosis in 15,792 adults. Study protocols were approved
for protection of human subjects. Participants were selected
from the entire population by probability sampling from
four US communities: Forsyth County, NC; Minneapolis,
MN; Washington County, MD; and Jackson, MS (where
only African Americans were sampled). Specific details
of the ARIC study are published elsewhere.13 Our analysis
was limited to ARIC participants aged 45–64 years old at
baseline, who provided information on respiratory symptoms
and diagnoses, medical history, and who underwent adequate
pulmonary function testing at the baseline examination.
The original CHS cohort consisted of 5201 subjects
selected using Medicare eligibility lists provided by the US
Healthcare Financing Administration for four communities:
Forsyth County, NC; Pittsburgh, PA; Sacramento County,
CA; and Washington County, MD from May 1989 to
May 1990. Analysis was limited to subjects who provided
information on respiratory symptoms and diagnoses, medical
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history, and smoking status, and who underwent a clinical
exam and spirometric testing at baseline and 4 years. Details
of the CHS are published elsewhere.14

Definition of variables
Demographic data used in this analysis were age (in 5 year
categories for ARIC and 4 year categories for CHS), sex, race
(black, white, other), education (less than 12 years, 12 years, and
more than 12 years). The study participants were categorized
into normal and elevated fibrinogen values with a cut off value
of greater than 393 mg/dL (corresponding to the top decile)
and six lung function categories based on modified Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
criteria; classification is based on “pre-bronchodilator”
response. GOLD Stage 3 or 4 (forced expiratory volume
in 1 second (FEV1)/forced vital capacity (FVC) ,0.70 and
FEV1 ,50% predicted), GOLD Stage 2 (FEV1/FVC ,0.70
and FEV1 .50 to ,80% predicted), GOLD Stage 1 (FEV1/
FVC ,0.70 and FEV1 .80%), restricted (FEV1/FVC .0.70
and FVC ,80% predicted), GOLD Stage 0 (presence of
respiratory symptoms in the absence of any lung function
abnormality), and no lung disease.
We included in the analyses potential confounders
of CVD at baseline (subjects reporting a diagnosis of a
previous myocardial infarction, stroke, heart failure, angina
or transient ischemic attack, and excluding hypertension).
Smoking status included current, former, and never smokers.
Respondents with a positive response to “Have you ever
smoked cigarettes?” and “Do you now smoke cigarettes?”
were classified as “ever smokers” and “current smokers,”
respectively. Pipe or cigar smokers were also considered
as “smokers.” Subjects were classified as having diabetes
if they reported either a diagnosis of diabetes at baseline or
had impaired fasting or post-glucose load levels (140 mg/dL)
upon examination. Body mass index was categorized as
“Underweight” (,20), “Normal” (20–24), “Overweight”
(25–29), and “Obese” (30).

Laboratory methods – fibrinogen
In ARIC, blood was drawn after an 8-hour fasting
period with minimal trauma from an antecubital vein.
Samples were processed by a standardized protocol and
stored at -70°C until assayed at the ARIC Hemostasis
Laboratory at the University of Texas Medical School,
Houston, TX. Detailed methods for blood processing
and measurement of hemostatic variables have been
published elsewhere.15 Fibrinogen was measured by the
thrombin-time titration method.16 Reliability coefficients
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obtained from repeated testing of individuals over several
weeks were 0.72 for fibrinogen.16
In CHS, baseline fibrinogen levels in 1989–1990 were
measured with a BBL fibrometer (Becton Dickinson,
Cockeysville, MD) by the Clauss methods with Dade fibrinogen calibration reference (Baxter-Dade, Bedford, MA) and
bovine thrombin (Parke-Davis, Lititz, PA).17

Pulmonary function testing
In both studies, spirometry was conducted using a volume
displacement, water-sealed spirometer. At least three acceptable spirograms were obtained from a minimum of five
forced expirations. The best single spirogram was identified by computer and confirmed by a technician. Quality
assurance was provided by the CHS Pulmonary Function
Center for CHS and the ARIC investigators for ARIC, and
the procedures followed contemporary American Thoracic
Society guidelines.18 Several measures of lung function were
used in this analysis: the FEV1, the FVC, and the FEV1/FVC
ratio. We used the prediction equations derived from the
Third National Health and Nutrition Examination Survey to
define the predicted values of FEV1 and FVC.19 We defined
a subject as having a respiratory symptom if they reported
cough, phlegm, dyspnea, or wheeze.

Definition of outcomes
Death was defined as all-cause mortality. COPD-related
hospitalizations were people with hospitalization code of
ICD-9 490–496 at any time after baseline. Rapidly declining
lung function comprised of people who, between the first and
second spirometries, were in the highest quartile of FEV1
decline (determined as an absolute difference in the baseline
minus the follow-up FEV1 and divided by the interval between
the two tests to obtain FEV1 loss per year). Lung function
decline was also determined as a proportion of the baseline
FEV1 and relative to the predicted FEV1 at baseline, but only
the absolute difference was used in the analyses. We also
determined the proportion of people who were unable to
obtain a follow-up spirometry. The development of COPD
was defined as GOLD Stage 2 or higher disease in people who
at baseline did not have GOLD Stage 2 or higher disease.

Statistical analyses
Data analysis was completed with SAS (v 9.2; SAS Institute,
Cary, NC) and SUDAAN (v 9.0; RTI, Research Triangle
Park, NC). Descriptive statistics and frequency distributions
were calculated for the studied population and its relationship
to fibrinogen levels and predictors (GOLD Status, CVD,

International Journal of COPD 2012:7

Fibrinogen and COPD

smoking status, diabetes mellitus). Linear regression model
using SUDAAN procedure REGRESS was used to determine correlates of fibrinogen levels controlling for age, sex,
race/ethnicity, body mass index, smoking status, modified
GOLD stage, diabetes, CVD, and educational level. These
were replicated examining fibrinogen levels in the top decile
(.393.0 mg/dL) using the SUDAAN procedure RLOGIST,
controlling for these same potential confounders. Our primary
outcome of interest in the survival models was time to death
and COPD-related hospitalization. Cox proportional hazard
regression models were developed using the SUDAAN procedure SURVIVAL to account for differential follow-up in
cohort participants. (Censoring occurred at the date of death
on certificate or the date the participant was last known to
be alive for mortality, and date of hospitalization or date last
known to be alive for COPD-related hospitalization.) The
SUDAAN procedure RLOGIST was used to determine the
relation between fibrinogen levels and elevated fibrinogen levels and not having a follow-up spirometry, being in the highest
quartile of FEV1 decline, and having incident COPD.

Results
The combined cohorts of ARIC and CHS included 20,993
participants at baseline. We excluded 311 who had not
obtained fibrinogen levels, 209 who did not have pulmonary function testing done, and 281 subjects missing other
key baseline data leaving 20,192 subjects in the combined
cohorts. The mean follow-up time was 9.7 years, with a
maximum of 12.1 years. By the end of the follow-up time,
2995 subjects (14.8%) had died.
Table 1 shows the distribution of age, sex, race/ethnicity,
body mass index, smoking status, modified GOLD stage,
diabetes mellitus, CVD, and educational level, including the
actual numbers of studied subjects and the percentage. This
Table also reports the mean fibrinogen levels, the proportion
of subjects with fibrinogen levels .393.0 mg/dL, and the
deaths per 1000 person-years of follow-up.
Tables 2 and 3 report the correlates of fibrinogen levels
(Table 2) and the correlates of elevated fibrinogen levels
(Table 3). There was considerable overlap between these
two analyses; for example, in both analyses older age,
current smoking, and the presence of diabetes or CVD
were associated with higher fibrinogen levels. The presence
of severe or very severe COPD was one of the strongest
predictors of fibrinogen levels, with a mean increase of
24.71 mg/dL (standard error 3.13 mg/dL) in the linear
regression models and an odds ratio for elevated fibrinogen
of 2.28 (95% confidence interval: 1.79–2.95).
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Table 1 Demographic characteristics and fibrinogen levels of subjects included in the analysis
Covariate
Age
45–49
50–54
55–59
60–64
65–68
69–72
73–76
77–80
.80
Sex
Male
Female
Race-ethnicity
White
Black
Body mass index
,20
20–25
25–30
.30
Smoking status
Current smoker
Former smoker
 Never smoker
Modified GOLD stage
Stage 3 or 4
Stage 2
Stage 1
Symptoms only
Restrictive
 None
Diabetes mellitus
Yes
 No
Cardiovascular disease
Yes
 No
Education level
,12
12 years
.13 years
Total

n

%

Mean fibrinogen level in
mg/dL (standard error)

Proportion with
fibrinogen .393.0 mg/dL

Deaths per
1000 person years

4072
3968
3739
3507
1279
1465
973
690
499

20.2
19.7
18.5
17.4
6.3
7.3
4.8
3.4
2.5

292.5 (1.0)
301.1 (1.0)
308.6 (1.1)
313.2 (1.1)
316.0 (1.1)
319.8 (1.7)
318.9 (1.9)
324.0 (2.6)
333.9 (4.8)

6.6
8.5
9.5
10.6
11.6
13.9
12.5
15.5
18.2

3.8
6.3
10.7
17.6
18.3
26.0
37.0
60.0
108.5

9011
11,181

44.6
55.4

302.9 (0.7)
311.4 (0.6)

9.2
10.5

19.8
11.8

16,027
4165

79.4
20.6

304.1 (0.5)
321.0 (1.1)

8.7
14.9

15.4
15.0

800
6263
8073
5056

4.0
31.0
40.0
25.0

301.9 (2.5)
297.7 (0.8)
305.8 (0.7)
323.8 (1.0)

9.6
7.7
9.1
14.2

28.2
15.2
15.1
13.7

4929
7036
8227

24.4
34.9
40.7

323.4 (1.0)
302.1 (0.8)
303.0 (0.7)

14.2
8.9
8.2

18.6
16.9
12.0

585
2221
2669
4375
3071
7271

2.9
11.0
13.2
21.7
15.2
36.0

336.8 (3.1)
320.7 (1.5)
309.5 (1.3)
306.0 (1.0)
324.2 (1.3)
294.6 (0.7)

19.3
14.1
11.3
14.0
9.3
6.1

54.6
25.3
23.2
13.2
15.8
8.2

2519
17,673

12.5
87.5

328.3 (1.5)
304.7 (0.5)

16.8
9.0

32.6
13.1

3076
17,116

15.3
84.8

320.4 (1.3)
305.3 (0.5)

14.0
9.2

33.3
12.4

4937
6366
8889
20,192

24.5
31.5
44.0
100.0

322.1 (1.0)
307.0 (0.8)
300.0 (0.8)
307.6 (0.5)

14.1
9.5
7.9
9.9

24.3
12.4
12.7
15.1

Table 4 shows the proportion of participants with the
outcomes of interest. During follow-up, 14.8% of the cohort
died, 7.5% experienced a COPD-related hospitalization,
and 16.3% did not obtain a follow-up spirometry. The
table also shows 16,935 subjects had a follow-up spirometry
and of these, 14,848 did not have Stage 2 or higher COPD
at baseline. Of the latter, 4.9% were found to have Stage 2
or higher COPD in follow-up.
The quartiles of lung function change are displayed in
Table 5. The most rapidly declining quartile lost 127 mL
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of FEV 1 annually, corresponding to 4.7% (annually)
of their baseline value and 4.3% of their predicted
baseline value.
Table 6 displays the unadjusted and fully adjusted models
for either continuous fibrinogen or elevated fibrinogen
(.393 mg/dL) predicting death, COPD-related hospitalization,
missing spirometry, rapidly declining lung function, and
incident COPD. Fibrinogen was a significant predictor of all
of these outcomes with the exception of being in the most
rapidly declining FEV1 quartile.
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Table 2 Correlates of fibrinogen levels from linear regression
models (n = 20,192)

Table 3 Correlates of fibrinogen levels .393 mg/dL (top decile)
from logistic regression models (n = 20,192)

Covariate

Covariate

Age
45–49
50–54
55–59
60–64
65–68
69–72
73–76
77–80
.80
Sex
Male
Female
Race-ethnicity
White
Black
Body mass index
,20
20–25
25–30
.30
Smoking status
Current smoker
Former smoker
 Never smoker
GOLD stage
Stage 3 or 4
Stage 2
Stage 1
Symptoms only
Restrictive
 None
Diabetes mellitus
Yes
 No
Cardiovascular disease
Yes
 No
Education level
,12
12 years
.13 years

Beta
estimate

Standard
error

0
7.60
14.82
19.06
25.71
30.90
31.74
38.02
51.44

0
1.32
1.39
1.43
1.97
1.95
2.21
2.83
3.51

-7.36
0

1.01
0

0
15.39

0
1.24

-5.88
0
9.58
24.63

2.47
0
1.04
1.24

25.60
1.64
0

1.23
1.04
0

,0.001
0.116

24.71
12.04
7.68
15.44
3.05
0

3.13
1.66
1.48
1.47
1.17
0

,0.001
,0.001
,0.001
,0.001
0.009

11.22
0

1.55
0

,0.001

8.19
0

1.34
0

,0.001

7.46
3.90
0

1.21
1.01
0

,0.001
,0.001

P-value

,0.001
,0.001
,0.001
,0.001
,0.001
,0.001
,0.001
,0.001
,0.001

,0.001
0.017
,0.001
,0.001

Figures 1–3 depict the interaction between fibrinogen
levels .393 mg/dL and modified GOLD stage in predicting
mortality, COPD-related hospitalization, and incident COPD.

Discussion
This analysis determined that fibrinogen levels were related
to spirometrically determined obstructive lung disease, with
evidence of a dose-response effect for COPD. Subjects with

International Journal of COPD 2012:7

Age
45–49
50–54
55–59
60–64
65–68
69–72
73–76
77–80
.80
Sex
Male
Female
Race-ethnicity
White
Black
Body mass index
,20
20–25
25–30
.30
Smoking status
Current smoker
Former smoker
 Never smoker
GOLD stage
Stage 3 or 4
Stage 2
Stage 1
Symptoms only
Restrictive
 None
Diabetes mellitus
Yes
 No
Cardiovascular disease
Yes
 No
Education level
,12
12 Years
.13 years

Odds ratio

95% confidence
interval

1.00
1.30
1.42
1.62
2.01
2.67
2.44
3.29
4.48

1.00
(1.09, 1.54)
(1.19, 1.68)
(1.36, 1.93)
(1.59, 2.53)
(2.16, 3.30)
(1.90, 3.14)
(2.51, 4.29)
(3.36, 5.98)

0.93
1.00

(0.83, 1.04)
1.00

1.00
1.99

1.00
(1.77, 2.24)

0.97

(0.74, 1.26)

1.00
1.23
1.91

1.00
(1.08, 1.40)
(1.67, 2.19)

2.12
1.16
1.00

(1.86, 2.41)
(1.02, 1.31)
1.00

2.28
1.77
1.59
1.77
1.23
1.00

(1.79, 2.95)
(1.52, 2.14)
(1.34, 1.88)
(1.55, 2.13)
(1.07, 1.44)
1.00

1.47
1.00

(1.29, 1.67)
1.00

1.29
1.00

(1.14, 1.46)
1.00

1.26

(1.11, 1.42)

1.18
1.00

(1.05, 1.33)
1.00

more advanced COPD (Stages 3 or 4) had a greater elevation in fibrinogen (24.71 mg/dL, P = 0.0000) than GOLD
Stage 2 or GOLD Stage 1 disease (12.04 mg/dL, P = 0.0000
and 7.68 mg/dL, P = 0.0000 respectively), relative to people
with normal lung function. In addition, we determined that
higher fibrinogen levels were related to an increased risk of
death, COPD-related hospitalization, and the development
of COPD.
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Table 4 Proportion of subjects with the outcome of interest: death, any COPD-related hospitalization during follow-up, those missing
follow-up spirometry, highest quartile of FEV1 decline, and incident Stage 2 or higher COPD (among those free of COPD at baseline)
Covariate

Age
45–49
50–54
55–59
60–64
65–68
69–72
73–76
77–80
.80
Sex
Male
Female
Race-ethnicity
White
Black
Body mass index
,20
20–25
25–30
.30
Smoking status
Current smoker
Former smoker
 Never smoker
GOLD stage
Stage 3 or 4
Stage 2
Stage 1
Symptoms only
Restrictive
 None
Diabetes mellitus
Yes
 No
Cardiovascular disease
Yes
 No
Education level
,12
12 years
.13 years
Fibrinogen .393
Yes
 No
Total

Death
n = 20,192

COPD-related
hospitalization
n = 20,192

Missing follow-up
spirometry
n = 20,192

Highest quartile
of FEV1 decline
n = 16,935

Incident
Stage 2 COPD
n = 14,848

3.9
6.4
10.6
16.9
17.8
24.4
33.0
48.1
72.1

1.1
2.4
4.4
7.9
15.6
18.4
20.4
22.9
19.4

10.5
10.3
10.9
14.1
21.8
25.7
31.9
40.7
60.1

24.4
26.1
26.6
27.9
22.4
21.9
19.9
18.8
18.8

2.7
3.1
4.4
5.4
8.9
9.2
10.5
13.7
10.7

11.7
18.8

6.0
9.3

15.8
16.8

18.6
33.3

4.5
5.3

14.9
14.5

8.6
3.2

14.9
21.5

26.1
21.1

5.4
3.1

25.8
14.8
14.7
13.4

15.3
7.9
6.9
6.6

23.0
16.0
15.2
17.2

22.5
24.6
26.2
24.4

7.9
5.7
4.7
4.0

17.8
16.3
11.8

12.3
8.7
3.6

19.2
16.1
14.7

31.0
26.3
20.8

8.6
5.1
2.9

44.8
23.5
21.6
13.0
15.3
8.2

46.5
19.6
10.6
4.3
6.5
1.8

38.3
23.5
19.6
14.4
19.2
11.0

19.6
25.5
31.7
27.0
13.4
26.6

N/A
N/A
15.0
2.6
8.3
1.6

29.0
12.8

10.3
7.1

27.0
14.7

23.5
25.3

5.9
4.8

29.6
12.2

15.8
6.0

25.7
14.6

27.9
24.7

7.5
4.5

22.6
12.1
12.5

11.8
6.9
5.4

25.7
14.3
12.5

23.4
24.8
26.2

5.8
5.1
4.3

28.5
13.3
14.8

14.8
6.7
7.5

29.1
14.9
16.3

25.3
25.1
25.1

8.4
4.6
4.9

Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second.

Our findings are consistent with those of Dahl et al9
who showed that increased levels of plasma fibrinogen
were associated with reduced lung function and increased
risk of COPD, independent of smoking status. Jiang et al20
also found that higher levels of baseline fibrinogen were
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c ross-sectionally associated with lower lung function and
greater longitudinal declines in FEV1/FVC ratio in the
elderly. Two population based studies 21,22 showed that
stable COPD patients have a pro-inflammatory state with
increased levels of acute-phase reactants. Kalhan et al8 found

International Journal of COPD 2012:7

Dovepress

Fibrinogen and COPD

Table 5 Quartiles of lung function decline among subjects who had baseline and follow-up pulmonary function measurement (n = 16,935)
and baseline FEV1, the mean annualized change in their absolute FEV1, annualized FEV1 change as a percentage of the baseline value, and
annualized FEV1 change as a percentage of the baseline predicted FEV1 value
FEV1 change
quartiles

n

Baseline FEV1
(percent predicted)

Change in FEV1
(SD)

Change in FEV1 as
percentage of baseline (SD)

Change in FEV1 as
percentage of predicted (SD)

1
2
3
4

4322
4306
4307
4310

98.1
93.9
91.2
88.0

-127 (63)
-61 (10)
-28 (9)
33 (72)

-4.7 (2.6)
-2.4 (0.9)
-1.2 (0.6)
1.9 (6.0)

-4.3 (2.2)
-2.2 (0.5)
-1.0 (0.4)
1.2 (2.8)

Abbreviations: FEV1, forced expiratory volume in 1 second; SD, standard deviation.

that participants in the highest year 7 fibrinogen had greater
FEV1 and FVC decline.
This analysis demonstrates that fibrinogen levels in this
cohort were significantly related to a number of factors,
including age, sex, race/ethnicity, current smoking status,
overweight and obesity, presence of chronic diseases such
as CVD, diabetes mellitus, and COPD. A previous study22
has shown that obstructive and restrictive lung diseases
were predictors of increased levels of plasma fibrinogen. As
fibrinogen levels were only determined at baseline we cannot speculate whether elevated fibrinogen caused COPD or

COPD caused elevated levels of fibrinogen. It is still unknown
and uncertain how and why individuals with COPD develop
systemic inflammation. Whatever is the mechanism of COPD
development, previous studies have shown individuals with
accelerated decline in lung function are at an increased risk of
COPD hospitalizations in the future. Engstrom et al showed
increased incidence of hospital admissions for COPD in those
with raised fibrinogen.23
We have demonstrated an effect of elevated fibrinogen
on mortality, COPD-hospitalizations, and incident Stage 2
COPD in the overall cohort (Table 6). The finding of elevated

Table 6 Results of unadjusted and fully adjusted logistic and Cox proportional hazards models predicting death, any COPD-related
hospitalization during follow-up, those missing follow-up spirometry, highest quartile of FEV1 decline, and incident Stage 2 or higher
COPD (among those free of COPD at baseline), with fibrinogen (per 100 mg/dL increase) or fibrinogen .393 mg/dL as the main
predictors
Outcome

Risk per 100 mg/dL
increase in fibrinogen
(unadjusted)

Risk per 100 mg/dL
increase in fibrinogen
(adjusted)*

Risk among subjects
with fibrinogen
levels .393 mg/dL
(unadjusted)

Risk among subjects
with fibrinogen
levels .393 mg/dL
(adjusted)*

Death
n = 20,192
Hazard ratio
(95% confidence interval)
COPD-related hospitalization
n = 20,192
Hazard ratio
(95% confidence interval)
Missing follow-up spirometry
n = 20,192
Odds ratio
(95% confidence interval)
Highest quartile of
FEV1 decline
n = 16,935
odds ratio
(95% confidence interval)
Incident Stage 2 COPD
n = 14,848
Odds ratio
(95% confidence interval)

1.69 (1.62, 1.77)

1.31 (1.24, 1.38)

2.39 (2.18, 2.62)

1.54 (1.39, 1.70)

1.76 (1.66, 1.87)

1.30 (1.21, 1.39)

2.52 (2.22, 2.87)

1.45 (1.27, 1.67)

1.67 (1.58, 1.76)

1.25 (1.18, 1.33)

2.35 (2.12, 2.61)

1.52 (1.35, 1.71)

1.00 (0.95, 1.06)

1.07 (1.01, 1.14)

1.01 (0.89, 1.14)

1.08 (0.95, 1.23)

1.49 (1.34, 1.65)

1.17 (1.03, 1.33)

1.90 (1.52, 2.38)

1.36 (1.07, 1.74)

Note: *Adjusted for age, sex, race, education level, body mass index, smoking status, diabetes mellitus, cardiovascular disease, and GOLD stage.
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second.
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Figure 1 Risk of mortality by modified GOLD stage and elevated fibrinogen level.
Abbreviations: ARIC, Atherosclerosis Risk in Communities Study; CHS, Cardiovascular Health Study; GOLD, Global Initiative on Chronic Obstructive Lung Disease.

f ibrinogen and the higher risk of mortality, COPDhospitalizations, and incident Stage 2 COPD raises an
option that fibrinogen could be used as a biomarker of
disease activity in COPD and potential target for therapeutic
interventions.
To our knowledge, this is one of the few studies with
follow-up data, and although fibrinogen level was only
available at baseline, partial temporal association of
fibrinogen and lung function can be taken into account,
although other cohort studies with lung specimens, exacerbations, and imaging are needed to validate the findings.
The study has adequate sample size and power. Bias due

to investigator’s knowledge of disease or risk factor seems
unlikely since plasma fibrinogen was measured without the
knowledge of lung function test results or disease status
of subjects.
This analysis has several limitations. Analysis was
only done using baseline fibrinogen levels, as follow-up
fibrinogen levels were not available on all subjects. Another
limitation is the unavailability of post-bronchodilator lung
function- measurement, information on COPD exacerbations
other than hospitalized exacerbations, and lung imaging
for COPD. Not all subjects completed pulmonary function
testing, biasing our sample towards a healthier population.
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Figure 2 Risk of chronic obstructive pulmonary disease-related hospitalization by modified GOLD stage and elevated fibrinogen level.
Abbreviations: ARIC, Atherosclerosis Risk in Communities Study; CHS, Cardiovascular Health Study; GOLD, Global Initiative on Chronic Obstructive Lung Disease.
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From combined ARIC and CHS cohorts

Figure 3 Risk of incident chronic obstructive pulmonary disease by modified GOLD stage and elevated fibrinogen level.
Abbreviations: ARIC, Atherosclerosis Risk in Communities Study; CHS, Cardiovascular Health Study; GOLD, Global Initiative on Chronic Obstructive Lung Disease.

In addition, although we have adjusted for potential confounders there remains residual confounding due to COPD
disease pathology based on genetic constitution, nutritional
intake, environmental exposures, alcohol intake, and other
infections causing systemic inflammation. These findings
need to be replicated in other cohorts, including those with
longitudinal measurements of fibrinogen.

Conclusion
In conclusion, we have demonstrated that elevated plasma
fibrinogen was associated with COPD; predicting higher risk
of mortality, COPD-hospitalizations, and incident Stage 2
disease. Fibrinogen can serve as a biomarker of the systemic
component of COPD and may provide an option for targeting of interventions to patients with evidence of systemic
inflammation or provide a means of stratifying patients in
clinical trials. Future research is needed to evaluate whether
targeted reduction in plasma fibrinogen levels will result in
better COPD outcomes.
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